Clinical Trial

Trial Protocol ID USOR 20417_D933LC00001_BEGONIA

Trial Description

A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Andrew Mener, M.D.

Disease Types

Sponsor

  • AstraZeneca

ClinicalTrials.gov NCT ID

  • NCT03742102